Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Add To Watchlist

Recent & Breaking News (NYSE:BMY)

Bristol-Myers Squibb Grants Help K-12 Educators Bring Science to Life and Help Students Explore Their Interests in the Sciences and Science-Based Careers

Business Wire June 18, 2013

Key to Success, How to Profit: FSLR, NWSA, BMY and LULU

Marketwired June 18, 2013

Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals

PR Newswire June 17, 2013

Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma

Business Wire June 15, 2013

AstraZeneca and Bristol-Myers Squibb to Present New Data at American Diabetes Association 73rd Scientific Sessions®

Business Wire June 14, 2013

Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia® SC (abatacept) in China

Business Wire June 14, 2013

Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China

PR Newswire June 14, 2013

Perfect Trade Setups, How to Play ARNA, BMY, MO and GT

Marketwired June 13, 2013

AstraZeneca and Bristol-Myers Squibb Statement on Proposal by the American Diabetes Association for Independent Review of Incretin-Based Therapies

Business Wire June 12, 2013

The Reason It Trades, What's Moving GRPN, CTL, ALU and BMY

Marketwired June 12, 2013

ORENCIA® (abatacept) Shows Comparable Efficacy to Humira® (adalimumab) in Year Two Data from Head-to-Head Study in Patients with Moderate to Severe Rheumatoid Arthritis

Business Wire June 11, 2013

ORENCIA® (abatacept) Shows Comparable Efficacy to Humira® (adalimumab) in First Long Term Head-to-Head Study in Patients with Moderate to Severe Rheumatoid Arthritis[1]

PR Newswire June 11, 2013

Perfect Trade Setups, How to Play NLY, FCEL, BMY and WIN

Marketwired June 7, 2013

Health Canada Expands Indications of Abilify® (aripiprazole), to be the First Add-On Treatment for Major Depressive Disorder (MDD)

Canada NewsWire June 6, 2013

Strategy Behind Our Success, We Get in Early: EBAY, YHOO, BMY and CERP

Marketwired June 6, 2013

Bristol-Myers Squibb to Take Part in Goldman Sachs Global Healthcare Conference

Business Wire June 5, 2013

Perfect Trade Setups, How to Play JPM, BSX, BMY and EMC

Marketwired June 5, 2013

StockCall Pre-Market Review on BMY, LLY, ENDP, and AGN

Accesswire June 5, 2013

U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca's Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystrophy

Business Wire June 4, 2013

Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients with Advanced Melanoma

Business Wire June 2, 2013